Business Wire

Distributed Technologies Research Simplifies Global Payments

11.12.2024 10:00:00 CET | Business Wire | Press release

Share

Introduces Revolutionary B2B Payment Solutions

Distributed Technologies Research (DTR), a fintech company focused on simplifying global payments infrastructure, officially launched its technology platform today. DTR seamlessly bridges national payment systems around the world to make financial transactions efficient, secure and universally accessible.

Current payment networks suffer from inefficiencies – such as transfer costs, interchange fees, FX conversion charges, settlement delays and other opaque fees – that effectively act as an indirect tax on consumers worldwide. DTR’s innovative solutions mitigate these inequities with an adaptable, compliant and scalable payment systems architecture that is globally accessible to businesses of all sizes.

Our team has spent several years studying the systemic barriers within traditional payment systems. The amalgamation of national payments systems with blockchain technologies has the potential to eliminate the hidden tax on consumers,” said Akshay Naheta, Founder & CEO of DTR.

DTR has unveiled AmalgamOS™, a state-of-the-art technology stack designed to streamline money transfers and merchant payments. Leveraging its proprietary International Orchestration Network (ION), AmalgamOS™ enhances financial connectivity and security for businesses worldwide. Currently live and trusted by numerous merchants and corporate clients, AmalgamOS™ enables instant fiat-to-fiat, fiat-to-stablecoin and stablecoin-to-fiat transactions in over 40 countries, with a roadmap into more than 100 countries in 2025.

Key Features of AmalgamOS:

Enhanced Transaction Speed: Transactions settle in minutes, leveraging blockchains’ 24/7 operational capability.

Cost Efficiency: Reduced reliance on intermediaries drastically lowers transaction fees.

Global Reach: Currently operational for payouts in over 40 countries worldwide, with pay-in capabilities available across EU nations. The platform is consistently expanding, with new countries being added monthly to enhance global reach and accessibility.

Developer-Centric Design: Flexible API’s, easy-to-integrate widgets, comprehensive white-label solutions, and a merchant control panel provide extensive optionality through simple integrations.

DTR’s interdisciplinary team combines seasoned professionals from traditional finance, payment systems, blockchains and Web3 technology. “DTR is dedicated to its goal of redefining the payments ecosystem by fostering inclusivity and eliminating inefficiencies, benefitting millions of people worldwide. By leveraging blockchain technologies for transparency, security and instantaneous settlements, DTR is addressing the growing demand for efficient and scalable payments solutions,” said Naheta.

Stablecoin transaction volume reached $8.5 trillion(1) in the second quarter of 2024 alone, and the global cross-border payments market is projected to grow to $290 trillion by 2030 from $190 trillion in 2023(2). DTR is uniquely positioned to lead this global payment systems transformation.

About Distributed Technologies Research (DTR)

Distributed Technologies Research (DTR) is at the forefront of simplifying how businesses conduct secure and seamless money transfers globally. We connect disparate national payment networks to enable a worldwide, instantaneous payments ecosystem. Our proprietary AmalgamOS™ technology and International Orchestration Network (ION) provide next-generation payments infrastructure and solutions.

For more information, visit http://www.dtr.org/

About Akshay Naheta, Founder & CEO, DTR

Akshay Naheta founded DTR with a vision to simplify financial transactions through the creation of an advanced global payments infrastructure. He brings over 20 years of experience in finance and technology, with an intricate understanding of blockchains, financial markets and payment systems. Previously, he held senior executive roles at SoftBank Group, where he spearheaded numerous technology investments in industry leaders such as ARM, Auto1 and Nvidia.

Sources:

(1) a16z, State of Crypto Report 2024. https://tinyurl.com/yn9wwjzj
(2) FTX Intelligence, Cross-border payments market sizing data. https://tinyurl.com/bdr7nkdv

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210988080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye